1083326-18-4

Basic information

• Product Name: N-(5-bromopyridin-3-yl)methanesulfonamide
• Synonyms: N-(5-bromopyridin-3-yl)methanesulfonamide;Methanesulfonamide,N-(5-bromo-3-pyridinyl)-;3-Bromo-5-[(methylsulfonyl)amino]pyridine
• CAS NO: 1083326-18-4
• Molecular Formula: C₆H₇BrN₂O₂S
• Molecular Weight: 251.10098
• Mol File: 1083326-18-4.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(5-bromopyridin-3-yl)methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-bromopyridin-3-yl)methanesulfonamide(1083326-18-4)
• EPA Substance Registry System: N-(5-bromopyridin-3-yl)methanesulfonamide(1083326-18-4)

Safety Data

• Hazardous Substances Data: 1083326-18-4(Hazardous Substances Data)

Usage

General Description

"N-(5-bromopyridin-3-yl)methanesulfonamide" is a chemical compound that consists of a 5-bromopyridine group linked to a methanesulfonamide group. It is commonly used as a reagent in organic synthesis and pharmaceutical research. N-(5-bromopyridin-3-yl)methanesulfonamide has potential applications in medicinal chemistry, specifically in the development of new drugs. Its structure and properties make it suitable for use in the creation of novel pharmaceutical compounds with various therapeutic effects. Additionally, it may also have utility as a reagent in the synthesis of other organic molecules. Overall, "N-(5-bromopyridin-3-yl)methanesulfonamide" is a valuable chemical building block with potential applications in both research and development in the pharmaceutical industry.

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1198803-15-4 N-{5-[4-amino-1-(phenylsulfonyl)-1H-indazol-6-yl]-3-pyridinyl}methanesulfonamide 
• 1240285-46-4 {4-chloro-2-[(5-methylsulfonylaminopyridin-3-yl)ethynyl]phenoxy}acetic acid 
• 1201643-71-1 N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide 

Relevant articles and documents

CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are described herein.

FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF

Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3Kδ, and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt path